Where does PIC Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), PIC Therapeutics, Inc. ranks #49,599 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does PIC Therapeutics, Inc. hold?

PIC Therapeutics, Inc. holds 5 US utility patents granted between 2023 and 2025, spanning 2 technology areas.

What is PIC Therapeutics, Inc.'s Innovation Score?

PIC Therapeutics, Inc. has an Innovation Score of 42.8 out of 100 (top 30% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is PIC Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for PIC Therapeutics, Inc..

What does claim depth mean for PIC Therapeutics, Inc.'s patents?

PIC Therapeutics, Inc.'s patents average 19.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the PIC Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

PIC Therapeutics, Inc.

Q: What technology areas does PIC Therapeutics, Inc. focus on?

PIC Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 5 patents. Grants appear in 2 CPC subclasses total.

USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, PIC ranks #49,599 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.

#49,599
of 49,997 US assignees by volume: Top 30%
by Innovation Score (42.8/100): 19.4
avg claims per patent

USPTO PatentsView assignee plate

Corpus R49599 · US Corporation #49,599 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 5 grants
BOTTOM-DECILE #49,599/49,997
PHOTO-FINISH Photonstar LED
CPC-NARROW A61P · 2 areas
INNOV-PAR 42.8/100
CLAIMS-RICH 19.4 claims/avg
TYPE-USCORP US Corporation
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Photonstar LED Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
PIC Therapeutics · this assignee

43
3D Lighting… · lowest

7

What this shows PIC's Innovation Score is 42.8/100 (top 30% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where PIC's grants concentrate

PIC Therapeutics, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (3 grants) versus a trough of 1 in 2023. By volume, PIC sits between Photonstar LED Limited and Pike Enterprises, Inc..

PIC's three-year grant acceleration

PIC Therapeutics, Inc. shows 4 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Photonstar LED

5
Photospectra Heal…

5
Phynexus

5
Physician Network…

5
Picadeli AB

5
Piezo Studio

5
Pife

5
Pike Enterprises

5
PIC Therapeutics ◀

5

What this shows PIC holds 5 patents at rank #49,515, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near PIC

By rank, the assignees closest to #49,515 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in PIC's primary technology class.

PIC's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

43 Top 30% higher than 70% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

PIC Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	1	20.0%
2024	3	60.0%
2025partial year	1	20.0%

Which technologies does PIC Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C07D - Heterocyclic Compounds 5

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#49,599

of 49,997 tracked assignees

Innovation Score

42.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

PIC Therapeutics, Inc.'s patent record in context - here's where to go next.

PIC Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #49,599 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare PIC Therapeutics, Inc. against Photonstar LED Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.